A large and  
growing market

Addressing 2 leading causes of blindness for ~1 million patients

Glaucoma and cataracts are the 2 leading causes of blindness worldwide—and frequently coexist in the same patients. In the United States alone, approximately 1 million glaucoma and ocular hypertension (OHT) patients were expected to undergo cataract surgery in 2025.¹

3% to 4%

Projected year-over-year growth  in cataract surgery volumes

A growing patient opportunity

The number of cataract procedures performed in the US is expected to increase by 3% to 4% per year.²

By embedding glaucoma therapy directly into the cataract surgery workflow, SpyGlass aims to transform an existing, high-volume procedure into an opportunity for long-term IOP control—without requiring new techniques, devices, or infrastructure.^3*

A large and growing market

Addressing 2 leading causes of blindness for ~1 million patients

A growing patient opportunity

By embedding glaucoma therapy directly into the cataract surgery workflow, SpyGlass aims to transform an existing, high-volume procedure into an opportunity for long-term IOP control—without requiring new techniques, devices, or infrastructure.3*

See the evidence behind this opportunity.

Please confirm you wish to leave SpyGlassPharma.com

Please confirm you wish to open the SpyGlass LinkedIn page in another window.

A large and  
growing market

By embedding glaucoma therapy directly into the cataract surgery workflow, SpyGlass aims to transform an existing, high-volume procedure into an opportunity for long-term IOP control—without requiring new techniques, devices, or infrastructure.^3*

Please confirm you wish to leave
SpyGlassPharma.com